Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
Tóm tắt
The European Medicines Agency has suspended the use of ulipristal acetate (UPA) in the treatment of uterine fibroids and is reassessing its association with a risk of liver injury. Our objectives were to characterize the post-marketing reporting of drug-induced liver injury (DILI) with UPA and investigate the underlying pharmacological basis. We queried the worldwide FDA Adverse Event Reporting System and performed a disproportionality analysis, selecting only hepatic designated medical events (DMEs) where UPA was reported as suspect. The reporting odds ratios (RORs) were calculated, and we considered a lower limit of the 95% confidence interval (LL95% CI) > 1 as significant. Physiochemical/pharmacokinetic features were extracted to assess the risk of hepatotoxicity by applying predictive DILI risk models. Mifepristone and leuprolide were selected as comparators. A significantly higher proportion of liver disorders was reported for UPA than for mifepristone (2.9 vs. 0.8%; p < 0.00001) and leuprolide (2.9 vs. 1.6%; p = 0.015). As regards hepatic DMEs, statistically significant RORs were found for autoimmune hepatitis (N = 5; LL95% CI 16.8), DILI (n = 5; LL95% CI 5.9), and acute hepatic failure (N = 5; LL95% CI 9.3). No signals of DILI emerged for mifepristone and leuprolide acetate. UPA and mifepristone showed high lipophilicity and hepatic metabolism (predicted intermediate DILI risk). Leuprolide exhibited contrasting features, resulting in no DILI concern. Inhibition of different liver transporters and the presence of a reactive metabolite were also recognised for UPA. Different drug properties previously linked to the occurrence of DILI may partially explain the reporting pattern observed with UPA. Our “bedside-to-bench” approach may support regulators in the risk–benefit assessment of UPA.
Tài liệu tham khảo
Rabe T, Saenger N, Ebert AD, Roemer T, Tinneberg HR, De Wilde RL, Wallwiener M. Selective progesterone receptor modulators for the medical treatment of uterine fibroids with a focus on ulipristal acetate. Biomed Res Int. 2018;24(2018):1374821.
Ulipristal acetate (Esmya): restrictions on use. Drug Ther Bull. 2018;56(11):127. https://doi.org/10.1136/dtb.2018.11.000033.
European Medicines Agency. Esmya Article-20 procedure - Scientific conclusions. https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-scientific-conclusions_en.pdf. Accessed 12 Apr 2020.
European Medicines Agency. Esmya: new measures to minimise risk of rare but serious liver injury. https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_en-0.pdf. Accessed 12 Apr 2020.
Donnez J. Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril. 2018;110(4):593–5. https://doi.org/10.1016/j.fertnstert.2018.06.044.
Donnez J, Arriagada P, Marciniak M, Larrey D. Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program. Expert Opin Drug Saf. 2018;17(12):1225–32. https://doi.org/10.1080/14740338.2018.1550070.
Del Forno S, Degli Esposti E, Salucci P, Leonardi D, Iodice R, Arena A, Raimondo D, Paradisi R, Seracchioli R. Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience. Gynecol Endocrinol. 2019. https://doi.org/10.1080/09513590.2019.1680626(Epub ahead of print).
European Medicines Agency. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk. https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-review-started_en.pdf. Accessed 11 Apr 2020.
European Medicines Agency. Designated Medical Event (DME) list. 2016. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/signal-management#designated-medical-events-section. Accessed 8 Apr 2020.
Antonazzo IC, Poluzzi E, Forcesi E, Riise T, Bjornevik K, Baldin E, Muratori L, De Ponti F, Raschi E. Liver injury with drugs used for multiple sclerosis: a contemporary analysis of the FDA Adverse Event Reporting System. Mult Scler. 2019;25(12):1633–40. https://doi.org/10.1177/1352458518799598.
Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63(2):590–603.
DeHart RM, Morehead MS. Mifepristone. Ann Pharmacother. 2001;35(6):707–19.
Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 2002;41(7):485–504.
Raschi E, De Ponti F. Strategies for early prediction and timely recognition of drug-induced liver injury: the case of cyclin-dependent kinase 4/6 inhibitors. Front Pharmacol. 2019;24(10):1235. https://doi.org/10.3389/fphar.2019.01235.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: drug-induced liver injury. J Hepatol. 2019;70:1222–61. https://doi.org/10.1016/j.jhep.2019.02.014.
Ivanov S.M., Lagunin A.A., Rudik A.V., Filimonov D.A., Poroikov V.V. ADVERPred–web service for prediction of adverse effects of drugs. Journal of Chemical Information and Modeling, 2018; 58(1): 8–11 (https://doi.org/10.1021/acs.jcim.7b00568). http://www.way2drug.com/adverpred/. Accessed 11 Apr 2020.
Montanari F, Knasmüller B, Kohlbacher S, Hillisch C, Baierová C, Grandits M, Ecker GF. Vienna LiverTox workspace-a set of machine learning models for prediction of interactions profiles of small molecules with transporters relevant for regulatory agencies. Front Chem. 2020;7:899. https://doi.org/10.3389/fchem.2019.00899. https://livertox.univie.ac.at/. Accessed 11 Apr 2020.
Chen M, Borlak J, Tong W. A Model to predict severity of drug-induced liver injury in humans. Hepatology. 2016;64(3):931–40. https://doi.org/10.1002/hep.28678.
Mishra P, Chen M. Direct-acting antivirals for chronic hepatitis C: can drug properties signal potential for liver injury? Gastroenterology. 2017;152(6):1270–4. https://doi.org/10.1053/j.gastro.2017.03.012.
Ferrero S, Vellone VG, Barra F. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. Expert Opin Drug Metab Toxicol. 2018;14(1):107–16. https://doi.org/10.1080/17425255.2018.1417389.
Pohl O, Zobrist RH, Gotteland JP. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids. Reprod Sci. 2015;22(4):476–83. https://doi.org/10.1177/1933719114549850.
Sarkar NN. Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. Eur J Obstet Gynecol Reprod Biol. 2002;101(2):113–20.
Heikinheimo O. Clinical pharmacokinetics of mifepristone. Clin Pharmacokinet. 1997;33(1):7–17.
https://www.drugbank.ca/. Accessed 11 Apri 2020.
European Medicines Agency. Assessment report on Esyma, May 17, 2018. https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-prac-assessment-report_en.pdf. Accessed 12 April 2020.
Roth RA, Ganey PE. Intrinsic versus idiosyncratic drug-induced hepatotoxicity–two villains or one? J Pharmacol Exp Ther. 2010;332(3):692–7.
Meunier L, Meszaros M, Pageaux GP, Delay JM, Herrero A, Pinzani V, Dominique HB. Acute liver failure requiring transplantation caused by ulipristal acetate. Clin Res Hepatol Gastroenterol. 2020. https://doi.org/10.1016/j.clinre.2020.02.008(Epub ahead of print).
Shah I, Putnam T, Daugherty E, Vyas N, Chuang KY. Mifepristone: an uncommon cause of drug-induced liver injury. Gastroenterol Res. 2019;12(3):181–4. https://doi.org/10.14740/gr1188.
Funke K, Rockey DC. Cholestatic drug-induced liver injury caused by mifepristone. Hepatology. 2019;69(6):2704–6. https://doi.org/10.1002/hep.30465.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Leuprolide. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. 2018.
Pérez-López FR, Ornat L, Ceausu I, Depypere H, Erel CT, Lambrinoudaki I, Schenck-Gustafsson K, Simoncini T, Tremollieres F, Rees M, EMAS. EMAS position statement: management of uterine fibroids. Maturitas. 2014;79(1):106–16. https://doi.org/10.1016/j.maturitas.2014.06.002.
Laberge PY, Murji A, Vilos GA, Allaire C, Leyland N, Singh SS. Guideline No. 389-medical management of symptomatic uterine leiomyomas—an addendum. J Obstet Gynaecol Can. 2019;41(10):1521–4. https://doi.org/10.1016/j.jogc.2019.01.010.
Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev. 2017;11:CD000547. https://doi.org/10.1002/14651858.cd000547.pub2.
de Milliano I, Twisk M, Ket JC, Huirne JA, Hehenkamp WJ. Pre-treatment with GnRHa or ulipristal acetate prior to laparoscopic and laparotomic myomectomy: A systematic review and meta-analysis. PLoS One. 2017;12(10):e0186158. https://doi.org/10.1371/journal.pone.0186158(eCollection 2017).
Ghonim M, Magdy R, Sabbour M, Ghonim M, Nabhan A. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids. Int J Gynaecol Obstet. 2019;146(2):141–8. https://doi.org/10.1002/ijgo.12868.
Indraccolo U, Conzadori S, Greco P. Which is the destiny of ulipristal acetate for uterine fibroids? A commentary on the Italian medicines agency (AIFA) pronouncements. Recent Prog Med. 2019;110:98–9.
Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017;66(6):1154–64.